Mutations in some of the key genes that have been previously reported as predictive biomarkers of chemotherapy response in BC, such as DNA damage repair (DDR) genes ERCC2, ATM, RB1, and FANCC), FGFR3, ERBB2, and BRCA2, were also examined. This evidence concerns the gene FGFR3 and breast cancer.